Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

Shore Capital Partners has formed PhaseWell Research, a Nashville-based clinical research site company. No financial terms were disclosed. In conjunction with the formation, Carsten Bick has been ...

NRG Oncology recently reported the results of the phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and ...

Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene ...

Discover BiomX's Q2 2025 updates, including progress in phage therapy trials BX004 & BX211, financial highlights, and key insights into upcoming ...

Cash and equivalents (GAAP) totaled $13.1 million as of Q2 2025. These 10 stocks could mint the next wave of millionaires › Traws Pharma (NASDAQ:TRAW), a clinical-stage biopharmaceutical company ...

Research and development spending rose 14.3% compared to Q2 2024, reflecting a busy clinical pipeline, while the net loss (GAAP) increased to $10.4 million. These 10 stocks could mint the next wave of ...

Q2 2025 Earnings Call Transcript August 13, 2025 BiomX Inc. beats earnings expectations. Reported EPS is $-0.19, expectations ...

People with multiple sclerosis tend to have frequent doctor's appointments up to 15 years before diagnosis, recent research ...

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratu ...

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...